• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Although a key characteristic of age-related macular degeneration is injury to the central part of the retina, current findings present that tiny blood vessels that feed this area degenerate first. Narendra Pandala, PhD, and his colleagues need to target this first casualty of the illness by making use of adult-derived stem cells to the realm. To encourage the stem cells to repopulate the lost capillaries, the crew plans to develop a biomaterial that supports focused injection of the cells. One feature of their planned biomaterial, a kind of gel that can swell after injection, is an immunosuppressant that may act locally to protect the introduced cells from attack.

The group’s goal is to keep away from the necessity for systemic immunosuppressants in recipients of donated cells, which would normally be required for such transplants. To develop and characterize their biomaterial, https://stemcellprocedurescanada.com/https://stemcellprocedurescanada.com/ Dr. Pandala and his group can be using lab fashions of cell loss in the attention. They expect their work to yield an injectable stem cell supply system with attainable clinical applications that can be used for further analysis into the earliest changes in age-related macular degeneration. If successful, their strategy additionally would signify a possible therapy for age-related macular degeneration that may very well be efficient fairly early in the disease and stop further injury.